Home-based brain stimulation for symptoms in Huntington's Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the feasibility, acceptability, and safety of using transcranial direct current stimulation (tDCS) in patients with Huntington's Disease (HD) who are in the early to middle stages of the condition. The intervention aims to assess its efficacy in alleviating behavioral and cognitive symptoms associated with HD, such as apathy, irritability, and depression. Participants will receive active tDCS while maintaining stable medication doses for at least one month prior to the study. Caregivers will also be involved to support participants throughout the process.

Why it matters

Who can join: the full rules

Participant:

Inclusion Criteria:

* confirmed HD mutation carriers and/or established family history alongside typical symptoms (i.e. chorea) of HD;
* early (stages 1 and 2) or moderate (stage 3) stages according to Shoulson-Fahn
* exhibit mild to moderate behavioral symptoms defined by severity scores in the PBA-S between 1 and 3 for any of the evaluated symptoms and no symptoms with a severity score of 4
* stable doses of medications for at least one month
* Have a caregiver willing to be present during tDCS sessions and answer questionnaires.

Exclusion Criteria:

* unstable medical conditions
* history of epilepsy
* metallic objects in the brain
* Have a caregiver willing to be present during tDCS sessions and answer questionnaires.
* clinical diagnosis of major cognitive disorder or dementia
* Have risk of suicidal behavior, defined as any suicidal behavior or suicidal ideation of type 4 or type 5 based on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the 3 months prior to screening
* simultaneous participation in other clinical trial
* Individuals determined to be incapable of consent per past medical history or via assessment by the study staff at time of consent.

Caregiver:

Inclusion Criteria:

-willingness to participate in the study

Exclusion Criteria:

-motor/cognitive symptoms related to Alzheimer's disease or Huntington's disease that might impair the ability to assist the participant during the research study.

Where it's running

• The University of Texas Health Science Center at Houston
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Erin Stimming, MD — The University of Texas Health Science Center, Houston
• Study coordinator: Erin Stimming, MD
• Email: Erin.E.Furr@uth.tmc.edu
• Phone: (713) 500-7033

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pridopidine for Huntington's Disease: a 1-year, randomized, placebo-controlled study

  This trial tests whether pridopidine can slow the progression of Huntington's disease in adults compared with placebo over one year.

  Recruiting at 17 sites Phase 3 Prilenia · Birmingham, Alabama and 65 other locations · NCT07609108

• Low-intensity focused ultrasound targeting the globus pallidus to improve movement in Huntington's disease

  This trial tests whether different pulse frequencies of low-intensity focused ultrasound (LIFU) aimed at a deep brain target can safely reduce chorea and other motor symptoms in adults with Huntington's disease.

  Recruiting First Affiliated Hospital of Fujian Medical University · Fuzhou, Fujian · NCT07513844

• Safety and tolerability of human neural stem cell implants for Huntington's disease

  This research will test whether an implant of hNSC-01 human neural stem cells is safe and tolerable for adults with Huntington's disease.

  Recruiting Phase 1/2 University of California, Irvine · Irvine, California · NCT07451613

• SKY-0515 for adults with Huntington's disease

  This trial will test whether the oral drug SKY-0515 can lower harmful huntingtin protein and improve symptoms in adults aged 25 and older with genetically confirmed Huntington's disease.

  Recruiting at 19 sites Phase 2/3 Skyhawk Therapeutics, Inc. · Englewood, Colorado and 30 other locations · NCT07378644

• Votoplam for adults with early symptomatic Huntington's disease

  This trial will test whether votoplam (HTT227) is safe and can slow disease progression in adults with early symptomatic Huntington's disease.

  Recruiting at 117 sites Phase 3 Novartis · Birmingham, Alabama and 116 other locations · NCT07326709

• Comparing three social cognition tests in adults with early Huntington disease

  This project will test whether the DMASC-MC and two established social cognition tests can detect social thinking problems in adults with early Huntington disease.

  Recruiting Region Skane · Lund · NCT07253038

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.